Indian drugmakers face risks as Trump eyes tariffs on US imports of pharma

Q: How long will it take to read this news story?

The story "Indian drugmakers face risks as Trump eyes tariffs on US imports of pharma" has 610 words across 25 sentences, which will take approximately 3 - 6 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Indian drugmakers face risks as Trump eyes tariffs on US imports of pharma" was covered 2 days ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 344 news stories per day. It's most recent story was published 7 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #26270751</li><li>URL: https://beamstart.com/news/indian-drugmakers-face-risks-as-17399635116754</li></ul>

Business Standard Logo Business Standard 2d ago

Indian drugmakers face risks as Trump eyes tariffs on US imports of pharma - Business Standard

Quick Summary:

It exports to 100 countries and overseas sales accounted to 72.7 per cent of the company's total revenue in the year.

The company distributes over 200 generic products in the market.(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.

The company relies on its key generic drugs in oncology and immunology therapies for sales in the region, which rose 28 per cent from a year earlier.